AIT Bioscience Announces Collaboration with Perfinity Biosciences for Automated Protein Analysis -AIT Bioscience

AIT Bioscience Announces Collaboration with Perfinity Biosciences for Automated Protein Analysis


Tuesday, December 13, 2011
AIT Bioscience and Perfinity Biosciences today announced a collaborative relationship which will provide automated protein analysis demonstrations and contract research services to the pharmaceutical, biotech and academic research communities.
The new services resulting from the companies’ collaboration will leverage the Perfinity Workstation, a proprietary automated sample preparation platform that has demonstrated significant advances in the quality, speed and value for both the qualification and quantification of protein-based therapeutics and biomarkers. AIT Bioscience evaluated the technology and identified key application areas for their pharmaceutical and biotechnology customers. The installation at AIT Bioscience is the first time the Perfinity Workstation has been placed in a contract research organization (CRO) for the bioanalysis of protein therapeutics. The system also will be used to identify chemical differences in biosimilars relative to branded biologics.
The workstation is now in the service ready phase at AIT Bioscience’s new state-of-the-art laboratory in Indianapolis, which opened in September. The laboratory is convenient for customers of both companies to see proof of concept data on their own proteins in a single day’s visit.  Customers further have the option to purchase the system from Perfinity or outsource their analytical studies to AIT Bioscience.
“The explosion of protein-based therapeutics and biomarkers has resulted in a development bottleneck in the analysis of these complex molecules. The Perfinity Workstation, combined with our mass spectrometry expertise, has resulted in an automated solution that our customers are searching for. This solution not only delivers speed but unprecedented quality. We are excited to bring this technology to our customers and play a role in accelerating the development of their products to the benefit of human health,” said AIT Bioscience Chairman Michael A. Evans, Ph.D.
“Aligning our automated sample preparation technology with AIT Biosciences’ formidable mass spectrometry resources and expertise will provide customers a one stop solution to their protein analysis needs.  The validation of our technology by AIT Bioscience is another important milestone in our commercialization journey,” commented Perfinity Biosciences CEO Steven Plump.
About AIT Bioscience
AIT Bioscience, headquartered in Indianapolis, Ind., is a bioanalytical contract research organization supporting pre-clinical and phase I-III clinical trials. AIT Bioscience provides robust analytical methods, painless sample logistics, and rapid sample analyses that support programs through to the investigational new drug and new drug applications. AIT Bioscience has created a new standard for quantitative bioanalytical analysis and drug development in support of small biotech and large pharmaceutical companies. Learn more about AIT Bioscience at
About Perfinity Biosciences
Perfinity Biosciences ( is a leader in the development, manufacture and supply of products that automate protein separations and mass spec sample preparation. Perfinity Biosciences is located in the Purdue Research Park of West Lafayette, Ind.